Pseudohypoaldosteronism (PHA)

Pseudohypoaldosteronism (PHA) is a group of rare conditions where the body makes aldosterone normally (often in high amounts) but kidney or other tissues do not respond to it. Because the signal is not heard, the kidneys do not reabsorb enough salt (sodium) and do not excrete enough potassium. This causes low blood sodium (hyponatremia), high blood potassium (hyperkalemia), and often metabolic acidosis, even though aldosterone levels are high and kidney filtration is usually normal. In babies, this can look like poor feeding, vomiting, dehydration, and failure to thrive. Some genetic forms also affect sweat glands, lungs, and the gut, leading to very salty sweat, recurrent chest infections, and widespread salt loss. Medscape+2Orpha+2

There are primary (genetic) forms and secondary (transient/acquired) forms. Primary forms include PHA type 1 (renal/“autosomal dominant” due to mineralocorticoid receptor defects; and systemic/“autosomal recessive” due to epithelial sodium channel defects) and PHA type 2 (Gordon syndrome), which is a different disorder with hypertension and hyperkalemia due to increased sodium-chloride reabsorption in the distal tubule. Secondary PHA occurs mostly in infants with urinary tract infection (UTI) and/or urinary tract malformations, and resolves when the underlying problem is treated. Frontiers+4Orpha+4Orpha+4

---

Other names

• PHA (pseudohypoaldosteronism) – umbrella term. Medscape

• Primary mineralocorticoid resistance – commonly used for PHA type 1. OUP Academic

• Renal PHA1 / Autosomal dominant PHA1 (PHA1A) – kidney-restricted form from NR3C2 (mineralocorticoid receptor) variants. NCBI

• Systemic or generalized PHA1 / Autosomal recessive PHA1 (PHA1B) – multi-organ salt wasting from ENaC subunit (SCNN1A/B/G) variants. NCBI+1

• PHA2 / Gordon syndrome / Familial hyperkalemic hypertension – hyperkalemia with hypertension due to WNK1/WNK4/KLHL3/CUL3 variants. Genetic & Rare Diseases Info Center+1

• Secondary (transient) PHA – aldosterone resistance triggered by UTI/urinary tract malformation/obstruction in infants. Frontiers+1

---

Types

1.  PHA Type 1 – Renal/Autosomal Dominant (PHA1A)
   This type is restricted to the kidney and usually improves with age. It is caused by loss-of-function variants in NR3C2, the mineralocorticoid receptor (MR) gene, so the kidney cannot “hear” aldosterone. Babies present with salt-wasting and hyperkalemic acidosis, but many older children and adults become minimally symptomatic; aldosterone may remain elevated. NCBI+1
2. PHA Type 1 – Systemic/Autosomal Recessive (PHA1B)
   This more severe, lifelong form is due to inactivating variants in the epithelial sodium channel (ENaC) genes SCNN1A, SCNN1B, or SCNN1G. Because ENaC is expressed in kidney, colon, sweat and salivary glands, and airways, patients lose salt from multiple organs, have very salty sweat, recurrent respiratory infections, and persistent electrolyte problems that require high-dose sodium therapy. Orpha+1
3. PHA Type 2 (Gordon syndrome)
   A distinct condition marked by hyperkalemia with hypertension and metabolic acidosis, often with low renin and normal or high aldosterone. It results from variants in WNK1, WNK4, KLHL3, or CUL3, which increase NCC (thiazide-sensitive) transporter activity; treatment with thiazide diuretics corrects the abnormality. Genetic & Rare Diseases Info Center
4. Secondary/Transient PHA (acquired)
   Seen mostly in young infants during severe UTI, pyelonephritis, and/or urinary tract malformations/obstruction. Inflammation or high intrarenal pressures blunt aldosterone signaling in the tubules. The condition resolves when the infection/malformation is treated. Frontiers+1

---

Causes

1. NR3C2 (MR) loss-of-function variants → Renal PHA1 (autosomal dominant); kidney cannot respond to aldosterone. NCBI+1

2. SCNN1A variants (ENaC α-subunit) → systemic PHA1 with multi-organ salt wasting. PMC

3. SCNN1B variants (ENaC β-subunit) → systemic PHA1; recurrent hyperkalemia and salt loss. Frontiers

4. SCNN1G variants (ENaC γ-subunit) → systemic PHA1; severe neonatal presentation. OUP Academic

5. Compound ENaC variants (multiple subunits) → more severe systemic PHA1. OUP Academic

6. WNK1 variants → PHA2 with hyperkalemia + hypertension. Genetic & Rare Diseases Info Center

7. WNK4 variants → PHA2 with hyperkalemia + metabolic acidosis. Genetic & Rare Diseases Info Center

8. KLHL3 variants → PHA2D; often early-onset hypertension. National Organization for Rare Disorders

9. CUL3 variants → PHA2 subtype; severe, often pediatric hypertension. Genetic & Rare Diseases Info Center

10. Secondary PHA due to urinary tract infection (UTI) in infants. Frontiers

11. Secondary PHA due to urinary tract malformation (UTM) (e.g., VUR, posterior urethral valves). ScienceDirect

12. Secondary PHA due to obstructive uropathy/pyelonephritis. ScienceDirect

13. Secondary PHA associated with severe inflammatory renal injury (intrarenal “cytokine storm” effect). BioMed Central

14. Kidney transplant aldosterone resistance (down-regulated MR expression) – rare acquired aldosterone resistance. NCBI

15. Idiopathic secondary PHA (rare reports without UTI/UTM in neonates). J Clin Res Pediatr Endocrinol

16. Systemic PHA airway involvement (ENaC dysfunction) aggravates salt/water handling and respiratory infections (a disease-expression “cause” of severity). Orpha

17. Severe diarrheal sodium loss can unmask or worsen PHA in infants already predisposed (case-based). Pediatric Medicine

18. Prematurity with immature tubule function may amplify secondary PHA (observational pediatric series). Frontiers

19. Concurrent salt-losing nephropathies (rare overlaps) may present like or alongside PHA1 in infancy. Medscape

20. Rare MR functional defects (non-coding/promoter) documented in molecular series; phenotype renal PHA1. OUP Academic

---

Common symptoms and signs

1. Poor feeding and vomiting in early weeks of life, due to low sodium and high potassium. PMC

2. Dehydration (dry mouth, sunken eyes/fontanelle) from salt loss and low effective blood volume. Medscape

3. Failure to thrive / poor weight gain when salt wasting is persistent. Bioscientifica

4. Lethargy or unusual sleepiness, often from low sodium or acidosis. Medscape

5. Irritability (electrolyte shifts make babies uncomfortable). Medscape

6. Low or normal blood pressure in PHA1; high blood pressure in PHA2. Medscape+1

7. Muscle weakness or floppiness from hyperkalemia/acidosis. Medscape

8. Cardiac rhythm problems (dangerous with high potassium), sometimes seen on ECG. Medscape

9. Seizures in severe hyponatremia. Medscape

10. Very salty sweat and prickly heat-like rash in systemic PHA1. Orpha

11. Recurrent chest infections or cough/wheeze due to ENaC dysfunction in airways (systemic PHA1). Orpha+1

12. Frequent wet diapers / high urine sodium despite dehydration (paradoxical salt loss). Medscape

13. Abdominal pain or vomiting during UTIs in secondary PHA. Frontiers

14. Heat intolerance (losing salt in sweat) in systemic PHA1. Orpha

15. Symptoms starting in infancy for PHA1; later childhood/adolescence for many PHA2 cases. MedlinePlus+1

---

Diagnostic tests

A) Physical examination (bedside)

1. General hydration check (skin turgor, mucous membranes, sunken eyes/fontanelle) to gauge dehydration severity from salt loss. Medscape

2. Vital signs (temperature, heart rate, respiratory rate, blood pressure) to distinguish low/normal BP in PHA1 from hypertensive PHA2. Medscape+1

3. Growth assessment (weight, length, weight-for-age) to identify failure to thrive. Bioscientifica

4. Skin inspection for salt crystals/rash and signs of heat injury in systemic PHA1. Orpha

5. Respiratory exam for wheeze/crackles suggesting airway involvement or intercurrent infection in systemic PHA1. Orpha

B) “Manual”/bedside clinical tests

6. Orthostatic (supine-to-standing) BP/HR to look for volume depletion in PHA1; not expected in PHA2. Medscape

7. Bedside ECG to screen immediately for hyperkalemia-related arrhythmias (peaked T waves, QRS widening). Medscape

8. Urine dipstick and microscopy to screen for UTI (leukocyte esterase/nitrites) in suspected secondary PHA. Frontiers

C) Laboratory and pathological tests

9. Serum electrolytes: low Na, high K are the hallmark; chloride and bicarbonate help judge metabolic acidosis. Medscape

10. Arterial/venous blood gas to confirm normal anion gap metabolic acidosis in PHA1 or PHA2. Medscape

11. Plasma renin activity and serum aldosterone: both typically elevated in PHA1 (resistance), whereas renin is low and aldosterone normal/high in many PHA2. Medscape+1

12. Urine sodium and fractional excretion of sodium (FENa): inappropriately high despite hyponatremia in salt-wasting PHA1. Medscape

13. Urine potassium indices (e.g., transtubular potassium gradient, TTKG): inappropriately low K secretion in the face of hyperkalemia suggests aldosterone pathway resistance. Medscape

14. Inflammatory markers and culture/urine culture if secondary PHA is suspected, to document UTI. Frontiers

15. Sweat electrolyte testing (Na/Cl): often very high in systemic PHA1; helps explain heat intolerance and dehydration; rule out/consider CF differential. Orpha

16. Genetic testing panels for NR3C2 (PHA1A) and SCNN1A/B/G (PHA1B); and WNK1/WNK4/KLHL3/CUL3 when PHA2 is suspected; confirms the form and guides counseling. E-APEM+2MedlinePlus+2

17. Cortisol/ACTH to exclude primary adrenal insufficiency (a different cause of hyperkalemia and hyponatremia with low aldosterone). Medscape

18. Renal function (creatinine), urinalysis to ensure GFR is preserved and to look for tubulointerstitial injury. Medscape

D) Electrodiagnostic studies

19. 12-lead ECG for hyperkalemia changes and rhythm monitoring; repeat after treatment to ensure stabilization. Medscape

E) Imaging tests

20. Renal and urinary tract imaging (renal/bladder ultrasound; consider voiding cystourethrogram if reflux suspected) to find malformations/obstruction that drive secondary PHA; treatable causes that often resolve the electrolyte disorder. Chest imaging may be used if respiratory complications are suspected in systemic PHA1. ScienceDirect+1

Non-pharmacological treatments (therapies & others)

Each item includes: brief description (what to do), purpose, and mechanism (how it helps).

1. Emergency hyperkalemia protocol (hospital setting). Treat dangerous potassium quickly with cardiac stabilization and potassium-lowering steps. Purpose: prevent arrhythmias and death. Mechanism: calcium protects the heart; insulin/glucose, β-agonist nebulization, and bicarbonate shift potassium into cells; resins or dialysis remove potassium. FDA Access Data+2FDA Access Data+2

2. Aggressive IV isotonic fluids during salt-wasting crises. Use 0.9% sodium chloride to restore volume and sodium. Purpose: correct dehydration and hyponatremia. Mechanism: replaces sodium and water, improving perfusion and kidney delivery of filtered electrolytes. FDA Access Data

3. Oral sodium supplementation (between crises). In PHA1, frequent oral sodium chloride (sometimes very high doses in systemic ENaC disease) to keep sodium normal. Purpose: prevent recurrent dehydration and failure to thrive. Mechanism: replaces the sodium the kidney is losing. jcpres.com+1

4. Low-potassium diet (medical nutrition therapy). Limit high-potassium foods when hyperkalemia recurs. Purpose: reduce potassium load. Mechanism: lowers gut potassium absorption to reduce serum levels. Medscape

5. Dietitian-guided infant feeding plan. Adjust formula/breast-milk fortification and sodium content; monitor growth curves. Purpose: support weight gain while controlling electrolytes. Mechanism: matches calorie, fluid, and sodium needs to ongoing renal losses. jcpres.com

6. Frequent outpatient monitoring (electrolytes/acid-base). Check Na/K/CO₂ often, especially during illness. Purpose: catch swings early. Mechanism: lab-guided dose titration of salt, binders, and diuretics. jcpres.com

7. Sick-day rules. During vomiting/diarrhea, increase oral sodium, seek care early, and recheck labs. Purpose: avoid rapid decompensation. Mechanism: anticipates higher sodium losses and prerenal azotemia. jcpres.com

8. Avoidance of potassium-raising drugs. Avoid ACEi/ARB, spironolactone, eplerenone, amiloride, trimethoprim, NSAIDs where possible. Purpose: reduce iatrogenic hyperkalemia. Mechanism: these agents impair renal K⁺ excretion or shift K⁺ out of cells. Medscape

9. Nebulized β-agonist (as a non-pill adjunct). Albuterol via nebulizer during acute hyperkalemia lowers K⁺ within minutes. Purpose: quick, noninvasive potassium shift. Mechanism: β₂ stimulation drives K⁺ into cells via Na⁺/K⁺-ATPase. PubMed+1

10. Bicarbonate therapy when acidotic. Correct metabolic acidosis to help potassium move intracellularly and improve ENaC function. Purpose: lower K⁺ and buffer acid. Mechanism: raises systemic pH; alkalemia shifts K⁺ intracellularly. FDA Access Data

11. Oral rehydration timing and spacing of meds. Separate oral potassium binders from other meds to prevent binding interactions. Purpose: maintain efficacy of all agents. Mechanism: patiromer label advises ≥3-hour separation from other oral drugs. FDA Access Data

12. Salt-enriched weaning foods (older infants). Use low-potassium, higher-sodium recipes while monitoring BP and labs. Purpose: dietary partner to sodium tablets. Mechanism: compensates ongoing renal salt loss. jcpres.com

13. Home action plan for caregivers. Written plan: red-flag symptoms, dosing charts, and when to go to ER. Purpose: rapid, consistent response. Mechanism: reduces delay in treating emerging crisis. jcpres.com

14. Thiazide-responsive plan for PHA2. Lifestyle sodium moderation plus thiazide first-line for BP and K⁺. Purpose: turn off the overactive NCC pathway. Mechanism: thiazides block distal NCC, enhancing Na⁺ and K⁺ excretion. NCBI+1

15. Sweat/skin care in systemic PHA1. ENaC dysfunction increases salt loss in sweat; prevent dermatitis and dehydration. Purpose: comfort and fluid balance. Mechanism: reduces cutaneous salt/water loss irritation. MedlinePlus

16. Infection-prevention basics. Vaccinations on schedule; early treatment of gastroenteritis. Purpose: avoid triggers of electrolyte decompensation. Mechanism: fewer dehydration episodes → fewer crises. jcpres.com

17. Education to avoid salt substitutes (often potassium-based). Purpose: prevent unrecognized K⁺ loading. Mechanism: common salt substitutes contain KCl. Medscape

18. Dialysis (as rescue). For refractory, life-threatening hyperkalemia or renal failure. Purpose: remove potassium directly. Mechanism: diffusion and convection clear K⁺ from blood. Medscape

19. Genetic counseling. Explain inheritance (AD NR3C2 vs AR ENaC; PHA2 genes). Purpose: family planning and early testing. Mechanism: targeted testing and anticipatory care. MedlinePlus+1

20. Transition-of-care planning. Structured handover from pediatrics to adult nephrology for persistent cases. Purpose: maintain adherence and monitoring. Mechanism: prevents loss to follow-up. jcpres.com

---

Drug treatments

For each, I note class, typical dosing/time (from label where available), purpose/mechanism, and key side effects/warnings. Some uses here (e.g., insulin/glucose for hyperkalemia) are standard of care but off-label for PHA specifically; labels are cited for safety and dosing fundamentals.

1. Patiromer (VELTASSA). Potassium binder. Dose/time: start 8.4 g once daily, titrate; separate ≥3 h from other oral meds; not for emergency use due to delayed onset. Purpose/mechanism: binds K⁺ in colon to lower serum K⁺. Side effects: constipation, hypomagnesemia; drug-binding interactions. FDA Access Data+1

2. Sodium zirconium cyclosilicate (LOKELMA). Potassium binder. Dose/time: 10 g TID up to 48 h for initial correction; then 10 g daily; not for emergency treatment. Purpose/mechanism: exchanges K⁺ for H⁺/Na⁺ in gut; lowers K⁺. Side effects: edema (sodium load). FDA Access Data+1

3. Sodium polystyrene sulfonate (KAYEXALATE). Potassium binder. Dose/time: per label; avoid in neonates orally; risk of colonic necrosis esp. with sorbitol. Purpose/mechanism: exchanges Na⁺ for K⁺ in colon. Side effects: GI necrosis, constipation, hypokalemia, sodium load. FDA Access Data+1

4. Hydrochlorothiazide (HCTZ). Thiazide diuretic (first-line for PHA2). Dose: label-guided antihypertensive dosing. Purpose/mechanism: blocks NCC in distal tubule → increases Na⁺/K⁺ excretion; lowers BP and K⁺ in PHA2. Side effects: hyponatremia, hypokalemia, hyperuricemia, photosensitivity. FDA Access Data+1

5. Chlorthalidone. Thiazide-like diuretic. Dose: per label (e.g., 12.5–25 mg daily). Purpose/mechanism: potent, long-acting NCC blocker effective in Gordon syndrome. Side effects: same class risks; monitor electrolytes/glucose/uric acid. FDA Access Data

6. Furosemide (LASIX). Loop diuretic. Dose: label-based; titrate to diuresis. Purpose/mechanism: increases distal sodium delivery and potassium excretion; useful if volume overloaded or for acute K⁺ reduction with fluids. Side effects: dehydration, electrolyte loss, ototoxicity at high doses. FDA Access Data

7. Calcium gluconate (IV). Cardiac membrane stabilizer in severe hyperkalemia. Dose: label-specific; slow IV administration. Purpose/mechanism: stabilizes myocardial cells, buying time while K⁺ is lowered. Side effects: tissue injury with extravasation; avoid mixing with bicarbonate solutions. FDA Access Data+1

8. Regular insulin (IV) with dextrose. Shifts K⁺ into cells rapidly. Dose: hospital protocols (e.g., 10 units IV regular insulin with 25 g dextrose); labels provide insulin/dextrose safety info. Purpose/mechanism: stimulates Na⁺/K⁺-ATPase → intracellular K⁺ shift. Side effects: hypoglycemia—monitor glucose. FDA Access Data+1

9. Albuterol nebulization. β₂-agonist. Dose: hyperkalemia studies often 10–20 mg nebulized; labels give administration/safety details. Purpose/mechanism: β₂ stimulation drives K⁺ into cells; adjunct to insulin/glucose. Side effects: tremor, tachycardia; monitor in arrhythmia. PubMed+1

10. Sodium bicarbonate (IV). Alkali therapy when acidotic. Dose: label-guided; titrate to pH/CO₂. Purpose/mechanism: raises pH, shifting K⁺ intracellularly and improving acidosis. Side effects: volume/Na⁺ load, overshoot alkalosis. FDA Access Data

11. 0.9% Sodium chloride (IV). Volume and sodium replacement. Dose: label-guided; individualized by weight and dehydration severity. Purpose/mechanism: corrects salt-wasting shock; improves renal K⁺ handling. Side effects: fluid overload if excessive. FDA Access Data

12. Dextrose/saline infusions (various strengths). Supportive fluid therapy. Purpose/mechanism: restore fluid/electrolyte balance and allow safe insulin delivery. Side effects: hyperglycemia, electrolyte shifts. FDA Access Data

13. Oral sodium chloride tablets (1 g). Electrolyte replenisher. Dose: individualized; often multiple grams/day in systemic PHA1. Purpose/mechanism: replaces ongoing salt losses. Side effects: edema/HTN risk—monitor. dailymed.nlm.nih.gov

14. Fludrocortisone. Mineralocorticoid. Role: can help some renal (NR3C2) PHA1 but is usually ineffective in systemic ENaC PHA1; may be used during diagnostic uncertainty. Side effects: hypertension, edema, hypokalemia. Mechanism: attempts to amplify mineralocorticoid signaling. Merck Manual+1

15. Sodium chloride parenteral solutions (various). For dilution and IV therapy as per label. Purpose/mechanism: controlled sodium delivery in hospital care. Side effects: as above. FDA Access Data

16. Insulin protocols (safety). See human regular insulin labels. Purpose/mechanism: reinforce safe dosing and hypoglycemia monitoring when used for K⁺ shift. Side effects: hypoglycemia. FDA Access Data

17. Adjunct loop + isotonic fluid (acute K⁺ lowering). Combine furosemide with normal saline for kaliuresis when volume replete. Purpose/mechanism: increases distal sodium delivery → K⁺ excretion. Side effects: dehydration/electrolyte loss. FDA Access Data

18. Monitoring for binder interactions. Patiromer separation ≥3 h; similar caution with SPS. Purpose/mechanism: avoid reduced absorption of other meds. Side effects: therapeutic failure if not separated. FDA Access Data+1

19. Albuterol HFA (inhaler) safety notes. Potassium can drop with high doses; monitor. Purpose/mechanism: supports nebulized therapy data; label highlights K⁺ changes and cardiac cautions. Side effects: hypokalemia, tachycardia. FDA Access Data

20. Clinical evidence anchor for albuterol in hyperkalemia. Dialysis patients study and modern kinetic work. Purpose/mechanism: documents dose-dependent K⁺ fall and safety considerations. Side effects: as above. PubMed+1

---

Dietary molecular supplements

There are no special “molecular supplements” proven to fix PHA itself; care is about salt in, potassium down, fluids right. Below are nutrition aids often used clinically to support management (not to replace medicines). Always individualize with a dietitian and clinician.

1. Oral Sodium Chloride (NaCl) powder/tablets. Dose: by clinician; often multi-gram/day in systemic PHA1. Function/mechanism: replaces renal sodium losses; prevents hyponatremia/dehydration. dailymed.nlm.nih.gov

2. Glucose polymers (energy supplement). Dose: per weight/needs. Function: extra calories to support growth. Mechanism: improves weight gain, reducing catabolic stress during salt-wasting phases. jcpres.com

3. Oral rehydration solution (ORS) strategy. Dose: per diarrheal losses. Function: balanced water/electrolyte intake. Mechanism: prevents dehydration and sodium deficits during illness. jcpres.com

4. Low-potassium fortifiers/recipes. Function: reduce dietary K⁺ load. Mechanism: less intestinal K⁺ absorption → lower serum K⁺. Medscape

5. Sodium bicarbonate (oral, selected cases). Dose: as per labs and clinician. Function: corrects chronic acidosis. Mechanism: raises serum bicarbonate; may modestly aid K⁺ control. FDA Access Data

6. Vitamin D and calcium (standard pediatric needs). Function: bone health during chronic illness. Mechanism: supports mineralization; not disease-specific for PHA. (Use per pediatric guidelines.) jcpres.com

7. Iron supplementation if deficient. Function: correct iron-deficiency anemia if present. Mechanism: restores hemoglobin, improves growth/energy. (Labs guide therapy.) jcpres.com

8. Iodine-adequate diet. Function: routine thyroid support in infants. Mechanism: ensures normal growth and development; not PHA-specific. jcpres.com

9. Protein-adequate feeding plan. Function: catch-up growth. Mechanism: supports lean mass and immune function during chronic salt loss. jcpres.com

10. Fiber-balanced diet. Function: avoid binder-related constipation (patiromer/SZC/SPS). Mechanism: improves bowel motility while monitoring K⁺ content of produce. FDA Access Data

---

Immunity booster / regenerative / stem-cell drugs

There are no FDA-approved “immunity booster,” regenerative, or stem-cell drugs for treating pseudohypoaldosteronism. Using such products for PHA would be unsupported and potentially unsafe. The proven, guideline-consistent approach is salt replacement, potassium control, and (for PHA2) thiazides, with emergency hyperkalemia protocols when needed. If a patient with PHA has a separate condition that truly requires immunotherapy or cell therapy, that should be managed under specialist care for that diagnosis—not for PHA. MedlinePlus+1

---

Surgeries / procedures

There is no disease-specific surgery that corrects PHA. However, procedures may be used for complications or rescue:

1. Temporary hemodialysis catheter placement for dialysis in refractory, life-threatening hyperkalemia. Why: rapidly remove K⁺. Medscape

2. Peritoneal dialysis catheter in infants if chronic dialysis ever becomes necessary due to severe, recurrent crises and kidney injury. Why: continuous home-based K⁺ removal when indicated. Medscape

3. Central venous access in unstable infants for reliable fluids/electrolytes and IV medications. Why: secure resuscitation and therapy delivery. FDA Access Data

4. Enteral feeding access (NG/PEG) in severe failure to thrive when oral intake is not enough. Why: ensure calories and sodium delivery. jcpres.com

5. Cardiac monitoring/defibrillation capability in severe hyperkalemia. Why: immediate response to arrhythmias. FDA Access Data

---

Preventions

1. Keep routine follow-up and frequent labs to adjust salt/binders/diuretics. jcpres.com

2. Sick-day plan (extra NaCl; early IV fluids if vomiting/diarrhea). jcpres.com

3. Avoid K⁺-raising medicines (ACEi/ARB, K-sparing diuretics, NSAIDs, high-dose trimethoprim). Medscape

4. Dietitian-led low-K⁺ meal plan; avoid KCl salt substitutes. Medscape

5. Ensure vaccinations and prompt infection care. jcpres.com

6. Teach caregivers about red-flags (poor feeding, lethargy, vomiting, arrhythmia symptoms). jcpres.com

7. Separate patiromer from other oral meds by ≥3 hours. FDA Access Data

8. Monitor blood pressure (especially PHA2 and those on fludrocortisone). NCBI

9. Regular growth monitoring in infants; adjust calories and sodium. jcpres.com

10. Keep an updated emergency letter with the hyperkalemia protocol for ER teams. FDA Access Data

---

When to see a doctor

Go to the emergency department immediately for poor feeding, persistent vomiting, unusual sleepiness, fainting, muscle weakness, palpitations, or seizures—these can signal dangerous hyperkalemia or severe hyponatremia. Families should bring their action plan and medication list. Routine care with nephrology/pediatrics is needed for dose adjustments, growth checks, and lab follow-up. jcpres.com

---

What to eat / what to avoid

Eat more / include: sodium-adequate meals as prescribed; low-potassium fruits/vegetables; balanced calories with adequate protein; fiber to prevent constipation if using binders; plenty of fluids during hot weather or illness (per clinician). Avoid/limit: potassium-rich foods when K⁺ is high; salt substitutes containing KCl; over-the-counter NSAIDs; herbal supplements that may raise K⁺; large unplanned fluid loads without medical advice if you have heart or kidney issues. Medscape

---

Frequently asked questions

1. Is PHA caused by low aldosterone? No—aldosterone is normal/high; the body resists it. MedlinePlus

2. Which babies have the worst symptoms? Systemic PHA1 (ENaC) tends to be more severe and long-lasting. MedlinePlus

3. Does it get better? Renal PHA1 often improves in early childhood; systemic PHA1 usually persists. MedlinePlus

4. What is PHA2/Gordon syndrome? A form with high BP + high K⁺ that improves with thiazides. NCBI

5. Can fludrocortisone fix PHA1? Sometimes helps renal PHA1 but generally fails in systemic PHA1. Merck Manual+1

6. What’s the fastest way to lower dangerous K⁺? Hospital hyperkalemia protocol: calcium for the heart, insulin/glucose, albuterol, bicarbonate (if acidotic), plus binders or dialysis. FDA Access Data+1

7. Are potassium binders safe for children? Patiromer label covers ≥12 years; others require specialist judgment. Always follow pediatric nephrology advice. FDA Access Data

8. Do we need a special “supplement” to cure PHA? No. Focus on salt in, K⁺ down, fluids right, and medicines. MedlinePlus

9. Why separate patiromer from other pills? It binds many medicines in the gut—keep ≥3 h apart. FDA Access Data

10. Can we use salt substitutes? Avoid KCl-based substitutes—they raise potassium. Medscape

11. What tests confirm PHA? Electrolytes, acid-base, renin/aldosterone pattern, and genetic testing (NR3C2 vs ENaC; WNK/KLHL3/CUL3 for PHA2). MedlinePlus+1

12. Is PHA2 a kidney failure disease? Not at first; GFR can be normal, but hypertension needs control. NCBI

13. What triggers crises? Gastroenteritis, heat, missed sodium, or high-K⁺ foods/meds. jcpres.com

14. Are nebulized β-agonists really effective for K⁺? Yes—studies show a prompt K⁺ drop; combine with standard measures. PubMed+1

15. Can adults have PHA? Yes—PHA2 often presents later; adult survivors of PHA1 may still need sodium and monitoring. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 04, 2025.

PDF Documents For This Disease Condition References